Every cell in our bodies is constantly renewing itself. While older cells age and die, new cells are constantly being created. Sometimes, this can lead to cells becoming damaged or remaining. Senescent cells, which are damaged cells, can have a negative effect on other cells nearby. This can alter the way that neighboring cells deal with inflammation, sugars, or proteins and can lead to metabolic problems.


Senolytics can be described as a group of drugs, supplements, or peptides that help to eliminate senescent cell. These drugs disable the survival mechanism of senescent cells.

Different tissues can become home to senescent cells. They can accumulate in different tissues. However, they can also be present in obesity and other metabolic diseases. These cells can cause dysfunction and secrete inflammatory cytokines, chemokines, and proteases, termed the senescence-associated secretory phenotype (SASP).

Senolytics can be used to eliminate problem-causing cells, according to ongoing research on animals and humans.

Senolytic Examples

Simply put, senolytic drugs can be used to treat metabolic and adipose dysfunction and inflammation.

Hypothesis-driven approaches were used to discover the first senolytic drugs, Navitoclax, Quercetin (Quercetin), Rapamycin, Fisetin, Fisetin, and Quercetin.

Sprycel is a brand name for Dasatinib, a cancer drug that treats certain types of leukemia in children and adults. It causes apoptosis of senescent cells through inhibition of the Src Tyrosine Kinase. Quercetin inhibits the anti-apoptotic Bcl-xL.

Quercetin, a naturally occurring flavonoid, has antioxidant and anti-inflammatory properties. It is used as a nutritional supplement. This drug combination targets and destroys senescent cell that are associated with multiple chronic age-related diseases.


Some of the preliminary research showed that dasatinib and quercetin reduced adipose tissue senescent cell burden within 11 days, with decreases in cellular senescence markers, decrease in cells with senescence-associated b-galactosidase activity, and adipocyte progenitors (similar to stem cells). The number of adipose tissue macrophages, which are attracted to, anchored and activated from senescent cells, was also reduced. The number of circulating SASP factors including interleukin 6 and Matrix metaloproteinases 9 and 12, as well as skin epidermal senescent cell numbers, was also reduced.

Senolytics have been shown to decrease the number of senescent cells and reduce inflammation, as well as alleviating frailty in people. Clinical trials are ongoing for eye diseases, diabetes, metabolic and skin diseases, Alzheimer’s disease and other diseases such as cardiovascular, liver and kidney diseases, heart, lung, and renal diseases.


Quercetin and Dasatinib are administered intermittently, so they don’t have to be taken every day. Both are effective in reducing the senescent cells burden. Because this therapy is intermittent, side effects are minimal.


  • May increase senescent marker cell numbers
  • May slow down cell proliferation and reduce the risk of developing age-related illnesses
  • May lessen age-dependent disc degeneration
  • May help improve metabolic disease
  • Improved insulin sensitivity and glucose tolerance may improve diabetes effects.
  • May reduce circulating inflammation mediators and promote adipogenesis
  • May improve neurodegeneration


Low blood cell counts, anemia and rash may be caused by dasatinib. You may also experience bleeding, pulmonary embolism, heart failure, prolonged QT syndrome, and other serious side effects. These side effects can be more frequent when dasatinib has been taken daily.


Quercetin’s safety and effectiveness on healthy individuals’ epigenetic aging rates. Start Date December 16th 2020, Primary Completion Dec 31 2021 and Study Completion June 30, 2022.

A second clinical trial is being conducted to determine the effect of Quercetin/Dasatinib on patients’ epigenetic aging rates. Researchers predict that Quercetin combined with Dasatinib will slow down cell proliferation, thereby slowing the rate of aging.

The Mayo Clinic’s Translational Geroscience Network is conducting clinical trials in senolytic aging that target fundamental mechanisms of aging to prolong health span, delay, prevent or treat cellular senescence-related diseases.

All these trials will provide evidence that natural and prescription senolytics are safe and effective. These trials will help to develop treatment protocols for patients suffering from multiple chronic diseases. Multiple disorders are often caused by aging mechanisms. It is exciting to consider the potential applications of senolytics for potentially relieving over 40 age-related diseases and dysfunctions.

This article was written by a peptide professional from Domestic Peptides. Looking for aicar for sale? Well, look no further. Welcome to Domestic Peptides where you’ll find a huge selection of Research Peptides for sale and Research Chemicals for Sale, all made in the USA.